Journavx for Pain Management: Toward Affordabil...

By Rene Pretorius

April 25, 2025

In this review I summarize the ICER 2025 evaluation report of suzetrigine (Journavx®), a new FDA-approved non-opioid oral analgesic. It targets the N...
Reassuring the Private Sector on National Health Insurance South Africa: A Pa...
A Shared-Value Model for Enhancing Diabetes Care in South Africa
Prior Authorization Elimination: Is Optum Rx moving towards Access Efficiency?
Systems Thinking in Pharmaceutical Access: Future-Proofing Value Strategy
Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal f...
NovoCare and the Rise of Direct-to-Consumer Pharmaceutical Access
CMS Price Negotiations: Bridging the Gap in US Drug Pricing
Access to Anti-Obesity Medication for Medicare and Medicaid
Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Pract...
Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA
CTO-PCI Technology for Heart Health in Egypt
Impact of Health Insurance on Advanced Prostate Cancer Treatment Costs